TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00426218
Drug: ACZ885
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01461967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses
Study: NCT01461967
Drug: RO5508887
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses
Study: NCT01461967
Drug: RO5508887
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses
Study: NCT00761332
Drug: antiresorptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment will be prescribed according to usual standard of care
Study: NCT01077284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching capsules
Study: NCT02023099
Drug: ABT-450/r/ABT-267
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267
Study: NCT02023099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT04117711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered once in the morning before breakfast
Study: NCT00472199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00213915
Drug: 12 g of L-arginine glutamate during 6 weeks twice a day
Normalized name: L-Arginine L-glutamate
DrugBank: Arginine glutamate (DB13207)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03296488
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
Study: NCT01901302
Drug: CB-5945
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01901302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02233504
Drug: Exjade® (deferasirox, ICL670)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03349281
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered via IV each cycle on day 2.
Study: NCT03349281
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered via IT injection to CNS negative subjects on day 16; and to CNS positive subjects on days 9, 16 and 23.
Study: NCT03349281
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered via IT injection to CNS positive subjects on days 9, 16, and 23.
Study: NCT00324571
Drug: Calcium-based phosphate binder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02222532
Drug: Tetronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral T3 was given 1 microgram/kgBW q6h since induction of anesthesia for 11 doses (for 60 hours)
Study: NCT02222532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was sacharum lactis, given q6h since induction of anesthesia for 11 doses (for 60 hours)
Study: NCT00082576
Drug: Azithromycin/Chloroquine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00396721
Drug: ACE inhibitor + statin
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d
Study: NCT00006747
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT01783821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized normal saline will be prepared to mimic the intervention arm, with the quantity, appearance and timing of the doses the being the same.
Study: NCT01536795
Drug: WR 279,396 with Gauze and Tape Dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days
Study: NCT00650416
Drug: Coreg® Tablets 12.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5mg, single dose fasting
Study: NCT00094549
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02696954
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
Study: NCT03792841
Drug: Cytochrome P450 (CYP) Cocktail
Normalized name: estradiol cypionate / testosterone cypionate Injectable Solution [Duo-Cyp]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluate the effect of co-administration of multiple dosing of acapatamab on plasma
Study: NCT03204318
Drug: Estradiol/norethindrone acetate
Normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
Study: NCT03204318
Drug: Estradiol/norethindrone acetate placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
Study: NCT02066389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration
Study: NCT00004171
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03873038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: Single dose of placebo will be administered via IV infusion on Day 1. Part 2: Three doses of placebo administered via IV infusion on Days 1, 3 and 5; Followed by single doses of placebo administered via IV infusion on Days 8, 15, and 22.
Study: NCT02467673
Drug: Micronized estradiol + progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of micronized estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
Study: NCT02467673
Drug: Nanoparticulate estradiol + progesterone
Normalized name: ESTRADIOL/PROGESTERONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of nanoparticulate estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
Study: NCT02095405
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SVT group: Oral tablets of Caffeine prior to the electrophysiology study in patients with SVT.~AF group: Dark chocolate and Caffeinated substances in patients with AF at the time of Ambulatory monitoring.
Study: NCT02055274
Drug: LY03003
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00807053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03479502
Drug: Methylprednisolone Injectable Product
Normalized name: methylprednisolone Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 intra-articular injections of Methylprednisolone Injectable Product spaced every two weeks
Study: NCT03479502
Drug: Doxycycline Injection
Normalized name: doxycycline Injection
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 intra-articular injections of Doxycycline Injection spaced every two weeks
Study: NCT03191526
Drug: KW-0761 0.3 mg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection every 12 weeks.
Study: NCT03191526
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection every 12 weeks.
Study: NCT00676663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching entinostat tablet orally once per week
Study: NCT00354809
Drug: GW679769
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00234299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325mg, one tablet orally every day, 6 months
Study: NCT02223299
Drug: deplin
Normalized name: Deplin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg daily for 30 days
Study: NCT01524068
Drug: Standard Steroid Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: One gm of methylprednisolone i.v., on day 0, followed by 40 mg/day i.v. on days 1-4, and days 6-12 (or the p.o. prednisone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone i.v. (or p.o. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the PI at each site.
Study: NCT04415151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets will be administered.
Study: NCT00098202
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02800941
Drug: Oral anticoagulant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment is delivered according to the usual practice.
Study: NCT03050541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01765608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01752634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PFS for s.c. administration.
Study: NCT02922894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo pill before-bedtime
Study: NCT03071679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT03196375
Drug: Placebo ODT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ODT taken three times daily for 28 days
Study: NCT00919542
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisolone 40mg daily then reducing regimen over 16 weeks
Study: NCT01451164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administered once daily
Study: NCT01973335
Drug: High-dose loop diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Patients receive the double of their daily maintenance dose of oral loop diuretics converted to mg bumetanide as an intravenous bolus after randomization.~* Patients continue to receive this dose daily on the next 3 days divided between two administrations with at least a 6 h interval for as long as they are considered volume overloaded by the treating cardiologist.~* If diuresis \<1,5 L while the patient is still considered volume overloaded by the treating cardiologist, the dose of bumetanide is doubled.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option.
Study: NCT01973335
Drug: Upfront therapy with oral spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to this group receive oral spironolactone (25mg) immediately after randomization and in the morning of each subsequent day unless the serum potassium level is \>5 mmol/L.~Note: Investigators and treating physicians are blinded to treatment allocation for this arm, but no matching placebo is provided, so patients are not.
Study: NCT01326000
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard iv chemotherapy
Study: NCT01326000
Drug: RO5083945
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1400 mg iv on Day 1 and Day 8, and every 2 weeks thereafter
Study: NCT01458951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral BID
Study: NCT00924833
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet BID
Study: NCT03249272
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
Study: NCT01153997
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single rFXIII placebo dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
Study: NCT03182634
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03182634
Drug: AZD6738
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01164917
Drug: AMG811
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twelve subjects will be randomized to receive AMG 811 in Period 1 and will receive AMG 811 Placebo in Period 2. The AMG 811 and AMG 811 Placebo will be administered by injection.
Study: NCT03453112
Drug: Foster 100/6mg NEXThaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler
Study: NCT02826577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose
Study: NCT02325245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, placebo will continue until 24 weeks.
Study: NCT04081831
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Follow clinical administration
Study: NCT01153997
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single rFXIII placebo dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
Study: NCT02408978
Drug: OXP005
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02408978
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01636947
Drug: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
Study: NCT02488590
Drug: ICS
Normalized name: ICSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
Study: NCT02488590
Drug: LABA + ICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
Study: NCT02488590
Drug: other
Normalized name: others
Approvals — FDA: no, EMA: no, PMDA: no
Description: An open label therapy or no therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
Study: NCT00322764
Drug: Uridine
Normalized name: Uridine
DrugBank: Uridine (DB02745)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04283474
Drug: XG005-03
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 different concentrations (1%, 5%, 10%) of XG005-03 topical formulation
Study: NCT04283474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo topical formulation
Study: NCT01840800
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02607280
Drug: DS-5565
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-5565 15 mg (for moderate renal impairment) or 7.5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
Study: NCT01534806
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac(0.5mg/kg) IV push
Study: NCT01534806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride 0.9% - 10 mL IV push
Study: NCT00253552
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02503644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical capsules without active substance
Study: NCT02368210
Drug: 122-0551 Foam
Normalized name: Rectal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Foam
Study: NCT00253552
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00732498
Drug: In-Zevalin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mCi slow IV push over 10 minutes days 1. Given within 4 hours after Rituximab.
Study: NCT00732498
Drug: Y-Zevalin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet counts from 100,000/mm3 to 149,000/mm3 will receive 0.3 mCi/kg. Platelet counts from \>/= 150,000/mm3 will receive 0.4 mCi/kg, not to exceed 32 mCi Y Zevalin. Slow IV push over 10 minutes, days 7,8 or 9 given within 4 hours after Rituximab.
Study: NCT03394508
Drug: ALK diluent 0,3% human albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralymphatic injection with 0.1 ml. 3 injections with 4-5 weeks interval
Study: NCT01107171
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tang-min-Ling pills analogue 6g,tid,po
Study: NCT00942188
Drug: LY2189102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 2 subcutaneous (SC) injections weekly for 12 weeks.
Study: NCT00942188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 2 SC injections weekly for 12 weeks.
Study: NCT03745105
Drug: Piroxicam Injectable Solution
Normalized name: piroxicam Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: prophylactic intraligamentary supplemental injection of 0.4 mL of 20 mg mL-1 piroxicam
Study: NCT00507065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01851980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline
Study: NCT03603275
Drug: New FVIII products
Normalized name: New Day Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kovaltry or Jivi prescribed by the treating Physician
Study: NCT01558245
Drug: tissue kallikrein
Normalized name: Tissue kallikrein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
Study: NCT02465606
Drug: Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone acetonide 0.1% cream will be supplied as single 454-g jars to be used on the body. Hydrocortisone 2.5% cream will be supplied as single 28-g tubes to be used on the face and intertriginous areas as indicated.
Study: NCT00941824
Drug: mycophénolate acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Day 0 to Day 7, 720 mg twice daily~* Day 8 to Day 30, 540 mg twice daily~* Day 30 to Day 90, 360 mg twice daily
Study: NCT00513292
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00366652
Drug: desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02167048
Drug: Psychostimulants
Normalized name: Other psychostimulants and nootropics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).~To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions.
Study: NCT03337932
Drug: Doxycycline 100 milligram Oral Tablet bid, 7 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive doxycycline for 7 days.
Study: NCT03337932
Drug: Doxycycline 100 milligram Oral Tablet bid, 14 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive doxycycline for 14 days.
Study: NCT03337932
Drug: Controls without a history of lyme disease.
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention.
Study: NCT02484638
Drug: CSL689
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant fusion protein, linking activated coagulation factor VII with albumin. Two dose levels (low dose, high dose) will be studied in Parts 1, 2, and 3.
Study: NCT06311448
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care during COVID-19 pandemic including steroids.
Study: NCT00123461
Drug: Hectorol (doxercalciferol capsules), 0.5mcg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02214862
Drug: [F18]-FDDNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: radiopharmaceutical tracer
Study: NCT02176460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet twice daily
Study: NCT00714688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2xplacebo once daily for 13 weeks
Study: NCT01540019
Drug: Paullinia cupana
Normalized name: Paullinia cupana seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg of Paullinia cupana as capsule, twice daily
Study: NCT01991678
Drug: 145 mg/m2 NKTR 102
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01991678
Drug: 120 mg/m2 NKTR 102
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01991678
Drug: 50 mg/m2 NKTR 102
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02077556
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually
Study: NCT00409500
Drug: AQW051
Approvals — FDA: no, EMA: no, PMDA: no